Work

Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps3178

Authors: Shiraj Sen, Aram F. Hezel, Anup Kasi, Nehal J. Lakhani, Alexander I. Spira, Rajwanth Veluswamy, Chenming Xu, Hisaki Fujii, Stanley Gill, Ho-Jin Lee, William Bennion McKean

Institutions: University of Rochester Medicine, University of Rochester, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai, Astellas Pharma (United States)

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410823194

FWCI: 1.301

Cites:

Cited by: 5

Related to: 10